Institute of Psychiatry, University of Bologna, Bologna, Italy.
Neuropsychobiology. 2011;63(1):1-7. doi: 10.1159/000321831. Epub 2010 Oct 20.
The aim of the present review is to summarize available evidence about the efficacy and side effects of novel antidepressants for the treatment of panic disorder.
A literature search was undertaken using MEDLINE, ISI web of knowledge and references of retrieved articles. The search included articles published in English up to September 2009. Both controlled and uncontrolled trials were included. The quality of the reviewed articles was also assessed.
Fourteen mainly poor-quality studies were included. Mirtazapine showed some efficacy in reducing the number and the severity of panic symptoms in many uncontrolled studies and was comparable to selective serotonin reputake inhibitors (SSRIs) in direct-comparison studies. Reboxetine was significantly more efficacious than placebo but less effective than SSRIs. Further uncontrolled studies suggested preliminary evidence for the use of milnacipran and duloxetine as well. All drugs were usually well tolerated.
Current studies do not yet provide convincing evidence supporting the efficacy of mirtazapine, reboxetine, milnacipran and duloxetine for the treatment of panic disorder patients. However, on account of positive preliminary results, further research is warranted.
本综述旨在总结新型抗抑郁药治疗惊恐障碍的疗效和副作用的现有证据。
使用 MEDLINE、ISI web of knowledge 和检索到的文章参考文献进行文献检索。检索包括截至 2009 年 9 月发表的英文文章。包括对照和非对照试验。还评估了综述文章的质量。
纳入了 14 项主要质量较差的研究。米氮平在许多非对照研究中显示出减少惊恐症状的数量和严重程度的一些疗效，并且在直接比较研究中与选择性 5-羟色胺再摄取抑制剂 (SSRIs) 相当。瑞波西汀与安慰剂相比明显更有效，但不如 SSRIs 有效。进一步的非对照研究也表明米那普仑和度洛西汀的使用有初步证据。所有药物通常都有良好的耐受性。
目前的研究尚未提供令人信服的证据支持米氮平、瑞波西汀、米那普仑和度洛西汀治疗惊恐障碍患者的疗效。然而，鉴于初步的积极结果，需要进一步的研究。
Zotero 插件